WOCKPHARMANSEWockhardt Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Mon, 4 May, 2026 · 15:32 IST

Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations ); and in continuation to our letter bearing reference no. Ref. No.: WOCK/SEC/SE/2026-27/006 dated 28th April, 2026, we wish to inform you that the Board of Directors of the Company, at its meeting held today i.e. 4th May, 2026, inter-alia, has approved:i. the Audited Financial Results and Financial Statements (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026. Kindly find enclosed herewith:a. Audited Financial Results (Standalone & Consolidated) for the quarter and financial year ended 31st March, 2026 along with Audit Report issued by M/s. M S K C & Associates LLP, Statutory Auditors of the Company on the same (enclosed as Annexure I); and b. Declaration on unmodified opinion on Audit Report (enclosed as Annexure II) ii Enabling proposal for raising of funds by issue of equity shares / securities convertible into equity shares/ non-convertible securities or any combination thereof in one or more tranches of public and/or private offerings, Qualified Institutions Placement and/or on preferential allotment basis or any combination thereof or any other method as may be permitted under applicable law, subject to consent of the shareholders at the ensuing Annual General Meeting and such approvals and compliances as may be required.

Revenue Growth 20pctPat Growth 25pctPat NegativeExceptional ItemResults View source PDFExplain this filing

WOCKPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+8.3%Reaction day
₹1431.00
prior close
₹1500.10
announcement price
After-mkt
timing
Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.2%+8.1% vs market
Pharmaceuticals peers, median of 163sector-0.1%+8.5% vs sector

On the reaction day the stock moved 8.1 pts more than Nifty Smallcap 250 and 8.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.8
10m
+4.6
15m
+4.1
30m
+2.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+8.3+0.2+8.1-0.1+8.5
Next day
+17.4+2.0+15.4+1.5+15.9
2d
+14.0+3.0+11.0+2.4+11.7
3d
+12.5+3.2+9.3+2.9+9.7
4d
+13.6+2.1+11.5+2.8+10.8
5d
+9.7-0.9+10.7+0.2+9.5
1w
+8.0-0.6+8.7+1.3+6.8
15d
+19.9+0.7+19.2+2.8+17.0
1m
+34.5+0.9+33.5+1.5+33.0
2m
+34.0+7.0+27.0+5.7+28.2
3m
+38.9+8.4+30.4+7.4+31.5
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Wockhardt Limited reported strong annual results for FY2026 ended March 31, 2026. Standalone revenue grew 24% to Rs 1,739 crore from Rs 1,402 crore, while consolidated revenue rose 12% to Rs 3,373 crore from Rs 3,012 crore. Standalone profit after tax turned around to Rs 317 crore from a loss of Rs 12 crore in FY2025, and consolidated PAT improved to Rs 199 crore from a loss of Rs 57 crore. The auditors issued an unmodified (clean) opinion on both standalone and consolidated results. Exceptional items included Rs 110 crore charge from deconsolidation of US subsidiaries under Chapter 7 bankruptcy, partially offset by Rs 35 crore gain from settlement of Dr. Reddy's legal dispute. The Board also approved a proposal to raise funds via equity or securities, subject to shareholder approval.

Likely market impact

The company has shown significant turnaround with strong revenue growth and return to profitability, which is positive for shareholders. However, the large exceptional charges from US business exit and the fund-raising proposal may create shareholder dilution concerns.